Francine Foss, MD
Research & Publications
Biography
News
Extensive Research Description
Over the last 10 years I have been a leader in the establishment of an international T cell lymphoma working group. I initiated a T Cell Lymphoma workshop at the International Conference on Malignant Lymphoma 12 years ago and from that workshop, the United States Peripheral T cell Lymphoma group was formed. I subsequently initiated the first T Cell Lymphoma Forum, an international meeting incorporating basic and clinical sciences related to T cell lymphomas. (www.tcellforum.com). This meeting is now recognized as the pre-eminent international T cell Lymphoma meeting. A number of collaborations have arisen from these meetings and there is now a world-wide effort to coordinate the care of patients with T cell lymphomas.
Another initiative that I undertook was to establish a T Cell Lymphoma Registry. I initiated and am the Principal Investigator for the COMPLETE T cell Registry (www. Clinical trials.gov/COMPLETE REGISTRY). This is a US based registry to determine the frequency of types of T cell lymphoma, physician’s treatment patterns, outcomes with therapy, and prognostic factors associated with common and rare subtypes. Thus far this registry has enrolled 500 patients in its first phase, and the second phase of enrollment is about to begin. I have also been a co-Founder of a European based registry, the TCELL PROJECT (www.TCELLPROJECT.org). This registry is similar to COMPLETE but includes pathologic review and includes many other countries in Asia, South America, and Europe as well as in the US. This registry has enrolled 1000 patients and is ongoing. In a recent initiative, I have collaborated with several countries in Latin American to initiate their own registry which will interface with our existing registries.
I was one of the founders of the United States Cutaneous Lymphoma Consortium. This organization includes oncologists, dermatologists, radiation oncologists, and pathologists and its goal is to develop novel clinical trials and to define clinical approaches for patients with cutaneous lymphomas. I also serve as a Co-Chair of the Registry Committee and have been instrumental in starting a patient registry for both T and B cell cutaneous lymphoma patients. This registry has a research focus. I am now the President of the USCLC.
Coauthors
Research Interests
Biological Factors; Graft vs Host Disease; Hodgkin Disease; Immune System Diseases; Leukemia, Hairy Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Sezary Syndrome; Skin Neoplasms; Leukemia, B-Cell; Leukemia, T-Cell; Leukemia, Prolymphocytic, T-Cell; Leukemia, Prolymphocytic, B-Cell; Composite Lymphoma; Chemicals and Drugs
Public Health Interests
Immunology
Selected Publications
- Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular LymphomaPotnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.
- Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populationsGirardi M, Ren J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.
- Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel DiscussionHodak E, Geskin L, Guenova E, Ortiz-Romero P, Willemze R, Zheng J, Cowan R, Foss F, Mangas C, Querfeld C. Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion American Journal Of Clinical Dermatology 2022, 24: 5-14. PMID: 36399227, PMCID: PMC9673193, DOI: 10.1007/s40257-022-00732-w.
- Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based AnalysisDi M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis Blood 2022, 140: 10818-10819. DOI: 10.1182/blood-2022-164915.
- Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene VicleucelMirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
- Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical CentersAllen P, Goyal S, Iyer S, Talluru S, Huen A, Greenwell I, Scribner J, Speegle S, Niyogusaba T, Rangarajan S, Mehta A, O'Leary C, Beaven A, Switchenko J, Ayers A, Bhatti S, Krishnasamy S, Porcu P, Sethi T, Foss F, Lechowicz M, Rozati S. Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers Blood 2022, 140: 9431-9433. DOI: 10.1182/blood-2022-170921.
- Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)Mirza A, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Ahmed S, Hematti P, Turtle C, Pasquini M, Gowda L. Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Blood 2022, 140: 4633-4635. DOI: 10.1182/blood-2022-163750.
- Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project NetworkHapgood G, Civallero M, Stepanishyna Y, Vose J, Cabrera M, Advani R, Pileri S, Manni M, Horwitz S, Foss F, Hitz F, Radford J, Dlouhy I, Chiattone C, Kim W, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M. Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network Blood 2022, 140: 1476-1478. DOI: 10.1182/blood-2022-158883.
- Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary EraBoussi L, Koh M, Han X, Peng L, Koh M, Eche I, Ford J, Singh S, Miranda E, Chiattone C, Van Der Weyden C, Prince H, Foss F, Yoon S, Kim W, Panchoo G, Verburgh E, Cuenca Alturas J, Al-mansour M, Manni M, Federico M, Cabrera M, Casadei B, Zinzani P, Yoshida N, Okatani T, Merrill M, Jacobsen E, O'Connor O, Marchi E, Jain S. Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era Blood 2022, 140: 10976-10978. DOI: 10.1182/blood-2022-162944.
- Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302Foss F, Kim Y, Prince H, Kuzel T, Yannakou C, Ooi C, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 Blood 2022, 140: 1491-1492. DOI: 10.1182/blood-2022-166916.
- A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative AnalysesOthman T, Ruel C, Frankel P, Merleev A, Luxardi G, Maverakis E, Abedi M, Ranganathan R, Zain J, Budde L, Mei M, Rosenberg A, Hoeg R, Costello C, Foss F, William B, Holland H, Villalona-Calero M, Sharon E, Tuscano J. A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses Blood 2022, 140: 9446-9447. DOI: 10.1182/blood-2022-167173.
- Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302Prince H, Geskin L, Akilov O, Kuzel T, Querfeld C, Ooi C, Xing D, Sauter N, Singh P, Czuczman M, Foss F. Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 Blood 2022, 140: 6577-6578. DOI: 10.1182/blood-2022-167564.
- Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignanciesZain, Iyer S, Sica R, Ho P, Hu B, Prica A, Weng W, Kim Y, Khodadoust, Palomba M, Foss F, Tipton K, Cullingford E, Horwitz S, Sharma A, Horwitz S. Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies European Journal Of Cancer 2022, 173: s21. DOI: 10.1016/s0959-8049(22)00591-3.
- Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysisShafagati N, Koh M, Boussi L, Park H, Stuver R, Bain P, Foss FM, Shen C, Jain S. Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis Blood Advances 2022, 6: 4740-4762. PMID: 35816645, PMCID: PMC9631658, DOI: 10.1182/bloodadvances.2022007425.
- Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCOlsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.
- 831 Proteasome inhibitor functional profiling in CTCLXu S, Lewis J, King A, Umlauf S, Carlson K, Foss F, Girardi M. 831 Proteasome inhibitor functional profiling in CTCL Journal Of Investigative Dermatology 2022, 142: s144. DOI: 10.1016/j.jid.2022.05.845.
- S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE.Michot J, Mehta A, Samaniego F, Bachy E, Zinzani P, Prica A, Colins G, Ribrag V, Wagner-Johnston N, El-Sharkawi D, O’Connor O, Wilcox R, Wang L, Wilson L, Sims M, Taylor J, Keer H, Foss F. S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE. HemaSphere 2022, 6: 118-119. DOI: 10.1097/01.hs9.0000843760.14993.43.
- S262: THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIESIyer S, Sica R, Ho P, Hu B, Zain J, Prica A, Weng W, Kim Y, Khodadoust M, Palomba M, Foss F, Tipton K, Cullingford E, He Q, Sharma A, Horwitz S. S262: THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES HemaSphere 2022, 6: 163-164. DOI: 10.1097/01.hs9.0000843940.96598.e2.
- Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell LymphomaAvery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.
- T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 285-308. PMID: 35276674, DOI: 10.6004/jnccn.2022.0015.
- 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous LeukemiaMirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev N, Engelhardt B, Kassim A, Savani B, Dholaria B, Jayani R, Perrault S, Schiffer M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Transplantation And Cellular Therapy 2022, 28: s139-s140. DOI: 10.1016/s2666-6367(22)00329-3.
- Comparative Outcomes for Mature T and NK/T-cell Lymphomas in People with and without HIV and to AIDS-Defining LymphomasKoh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Atlhoff K, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Comparative Outcomes for Mature T and NK/T-cell Lymphomas in People with and without HIV and to AIDS-Defining Lymphomas Blood Advances 2022, 6: 1420-1431. PMID: 35026839, PMCID: PMC8905704, DOI: 10.1182/bloodadvances.2021006208.
- Safety considerations with the current treatments for peripheral T-cell lymphomaSethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant ResearchMurthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.
- Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete CohortsKoh M, Merrill M, Koh M, Stuver R, Alonso C, Foss F, Mayor A, Gill M, Epeldegui M, Cachay E, Thorne J, Silverberg M, Horberg M, Atlhoff K, Nijhawan A, McGinnis K, Rabkin C, Napravnik S, Shen C, Jain S. Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts Blood 2021, 138: 1380-1380. DOI: 10.1182/blood-2021-147837.
- EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell LymphomasSethi T, Gerstein R, Schiffer M, Amin K, Agarwal S, Foss F. EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas Blood 2021, 138: 4547-4547. DOI: 10.1182/blood-2021-151238.
- Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart ReviewGirardi M, Johnson A, Carlson K, Huang X, Corman S, Edmundson P, Kale H, Rusibamayila N, Foss F. Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review Blood 2021, 138: 1405-1405. DOI: 10.1182/blood-2021-151116.
- A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01Foss F, Porcu P, Horwitz S, Izutsu K, Ishitsuka K, Kato K, Jin J, Du Y, Inoue A. A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01 Blood 2021, 138: 2533-2533. DOI: 10.1182/blood-2021-144676.
- Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell LymphomaWitzig T, Sokol L, Kim W, de la Cruz Vicente F, Caballero D, Advani R, de Oña R, Marin Niebla A, Terol M, Eva D, Bendris N, Ahsan J, Leoni M, Foss F. Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma Blood 2021, 138: 621-621. DOI: 10.1182/blood-2021-147279.
- Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-AnalysisShafagati N, Stuver R, Boussi L, Koh M, Park A, Bain P, Foss F, Shen C, Jain S. Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis Blood 2021, 138: 1431-1431. DOI: 10.1182/blood-2021-150315.
- Adverse cardiovascular events in patients treated with mogamulizumabKwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. DOI: 10.1016/j.ahjo.2021.100049.
- Poster: TCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary SyndromeFoss F, Ito T, Dwyer K, Herr F. Poster: TCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome Clinical Lymphoma Myeloma & Leukemia 2021, 21: s248. DOI: 10.1016/s2152-2650(21)01564-0.
- TCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary SyndromeFoss F, Ito T, Dwyer K, Herr F. TCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome Clinical Lymphoma Myeloma & Leukemia 2021, 21: s412. DOI: 10.1016/s2152-2650(21)01926-1.
- 558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignanciesRibrag V, Davar D, Garralda E, Curigliano G, Zain J, Mehta A, Minchom A, Sanborn R, Foss F, Oberoi H, Forero-Torres A, Ansell S. 558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies Annals Of Oncology 2021, 32: s615-s616. DOI: 10.1016/j.annonc.2021.08.1080.
- Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trialCowan R, Scarisbrick J, Zinzani P, Nicolay J, Sokol L, Pinter‐Brown L, Quaglino P, Iversen L, Dummer R, Musiek A, Foss F, Ito T, Rosen J, Medley M. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial Journal Of The European Academy Of Dermatology And Venereology 2021, 35: 2225-2238. PMID: 34273208, PMCID: PMC9290719, DOI: 10.1111/jdv.17523.
- New nonchemotherapy treatment options for cutaneous T-cell lymphomasXu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas Expert Review Of Anticancer Therapy 2021, 21: 1017-1028. PMID: 33554707, DOI: 10.1080/14737140.2021.1882859.
- Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro ScreeningsKing ALO, Mirza FN, Lewis JM, Umlauf S, Surovtseva Y, Carlson KR, Foss FM, Girardi M. Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings Journal Of Investigative Dermatology 2021, 142: 254-257. PMID: 34293349, DOI: 10.1016/j.jid.2021.04.035.
- FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMASIshitsuka K, Izutsu K, Maruyama D, Makita S, Jacobsen E, Horwitz S, Kusumoto S, Allen P, Porcu P, Imaizumi Y, Yamauchi N, Morishima S, Kawamata T, Foss F, Utsunomiya A, Nosaka K, Serbest G, Kato K, Adachi N, Tsukasaki K, Tobinai K. FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS Hematological Oncology 2021, 39 DOI: 10.1002/hon.14_2879.
- Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell LymphomaKwan JM, Odanovic N, Arbune A, Higgins A, Henry M, Greif D, Foss F, Baldassarre LA. Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma JACC Case Reports 2021, 3: 1018-1023. PMID: 34317676, PMCID: PMC8311348, DOI: 10.1016/j.jaccas.2021.04.001.
- SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).Garralda E, Sanborn R, Minchom A, Davar D, Curigliano G, Ribrag V, Mehta A, Foss F, Zain J, Forero-Torres A, Ansell S. SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress). Journal Of Clinical Oncology 2021, 39: tps2657-tps2657. DOI: 10.1200/jco.2021.39.15_suppl.tps2657.
- How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndromeSethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
- 672 JAK inhibitor functional profiling in CTCLKing A, Mirza F, Lewis J, Yumeen S, Kim S, Carlson K, Foss F, Girardi M. 672 JAK inhibitor functional profiling in CTCL Journal Of Investigative Dermatology 2021, 141: s117. DOI: 10.1016/j.jid.2021.02.702.
- Necrotic papulonodules on the legsZhou A, Damsky W, Girardi M, Foss FM, Vesely MD. Necrotic papulonodules on the legs JAAD Case Reports 2021, 11: 10-12. PMID: 33898676, PMCID: PMC8056172, DOI: 10.1016/j.jdcr.2021.03.012.
- 581 The Effect of Cyclophosphamide Pharmacogenomics on Cardiac, Hemorrhagic Cystitis, and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)Gerstein R, Schiffer M, Perreault S, Gowda L, Foss F, Isufi I, Seropian S. 581 The Effect of Cyclophosphamide Pharmacogenomics on Cardiac, Hemorrhagic Cystitis, and Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Transplantation And Cellular Therapy 2021, 27: s466-s467. DOI: 10.1016/s2666-6367(21)00606-0.
- 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT)Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.
- Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusionPerreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion American Journal Of Health-System Pharmacy 2021, 78: zxab072. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
- Gamma–Delta T‐cell LymphomasFoss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas 2021, 203-210. DOI: 10.1002/9781119671336.ch15.
- Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphomaJohnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Hasal SJ, De Vos S, Oki Y, Deng C, Foss FM. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma Experimental Hematology & Oncology 2021, 10: 15. PMID: 33602316, PMCID: PMC7893947, DOI: 10.1186/s40164-021-00203-8.
- 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell TransplantationSchiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.
- 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid TherapyPerreault S, Schiffer M, Zhao J, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy Open Forum Infectious Diseases 2020, 7: s353-s354. PMCID: PMC7776791, DOI: 10.1093/ofid/ofaa439.771.
- B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphomaKing ALO, Mirza FN, Lewis JM, Carlson KR, Huntington S, Foss FM, Girardi M. B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma JAAD Case Reports 2020, 8: 89-92. PMID: 33537387, PMCID: PMC7838714, DOI: 10.1016/j.jdcr.2020.12.025.
- Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell LymphomasLee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphomaPatel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
- Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902 Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.
- Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomasIsufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
- Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on RuxolitinibFoss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
- Screening Novel Agent Combinations to Expedite CTCL Therapeutic DevelopmentMirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.
- JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCLYumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.
- Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasisHornick N, Wang A, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis Journal Of The European Academy Of Dermatology And Venereology 2020, 34: e583-e585. PMID: 32277505, DOI: 10.1111/jdv.16451.
- Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort StudyLansigan F, Horwitz SM, Pinter-Brown LC, Carson KR, Shustov AR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Foss FM. Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study Clinical Lymphoma Myeloma & Leukemia 2020, 20: 744-748. PMID: 32532611, PMCID: PMC8447249, DOI: 10.1016/j.clml.2020.05.001.
- Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosisWang A, Hornick N, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis Journal Of The European Academy Of Dermatology And Venereology 2020, 34: e497-e499. PMID: 32249470, DOI: 10.1111/jdv.16416.
- Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomasFoss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko Y, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas American Journal Of Hematology 2019, 95: 151-155. PMID: 31709579, PMCID: PMC8025136, DOI: 10.1002/ajh.25674.
- DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphomaWang M, Kibbi N, Ring N, Siddon A, Foss F, Totonchy M. DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma BMJ Case Reports 2019, 12: e230641. PMID: 31570354, PMCID: PMC6768350, DOI: 10.1136/bcr-2019-230641.
- Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. Journal Of Clinical Oncology 2019, 38: 20-28. PMID: 31532724, PMCID: PMC6943974, DOI: 10.1200/jco.19.01056.
- Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryLansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry Acta Haematologica 2019, 143: 40-50. PMID: 31315113, DOI: 10.1159/000500666.
- A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphomaAfifi S, Mohamed S, Zhao J, Foss F. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma Expert Opinion On Drug Safety 2019, 18: 769-776. PMID: 31303060, DOI: 10.1080/14740338.2019.1643837.
- Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate* Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.
- Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registryStuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter‐Brown L, Pro B, Shustov AR, Foss FM, Jain S. Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry American Journal Of Hematology 2019, 94: 641-649. PMID: 30896890, PMCID: PMC7928240, DOI: 10.1002/ajh.25463.
- The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN) Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
- Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaO’Connor O, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d’Amore F, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR, . Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Journal Of Clinical Oncology 2019, 37: 613-623. PMID: 30707661, PMCID: PMC6494247, DOI: 10.1200/jco.18.00899.
- The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort studyPark SI, Horwitz SM, Foss FM, Pinter‐Brown L, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR, Investigators F. The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Cancer 2019, 125: 1507-1517. PMID: 30694529, PMCID: PMC8269282, DOI: 10.1002/cncr.31861.
- Hepatosplenic T-Cell LymphomasGowda L, Foss F. Hepatosplenic T-Cell Lymphomas 2018, 176: 185-193. PMID: 30596219, DOI: 10.1007/978-3-319-99716-2_9.
- Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015Miccio JA, Wilson LD, Kann BH, Jairam V, Beckta J, Foss FM, Yeboa DN. Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015 Anticancer Research 2018, 39: 253-259. PMID: 30591466, DOI: 10.21873/anticanres.13105.
- Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell LymphomaDavids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS. Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma Journal Of Clinical Oncology 2018, 36: jco.18.00359. PMID: 30359156, DOI: 10.1200/jco.18.00359.
- Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 studyO'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study American Journal Of Hematology 2018, 93: 1318-1326. PMID: 30094870, PMCID: PMC8260004, DOI: 10.1002/ajh.25243.
- Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 studyFlinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study American Journal Of Hematology 2018, 93: 1311-1317. PMID: 30033575, PMCID: PMC6220789, DOI: 10.1002/ajh.25228.
- Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantationKim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
- Clinical Activity of Pralatrexate in Patients with Cutaneous T-Cell Lymphoma Treated with Varying Doses of PralatrexateFoss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients with Cutaneous T-Cell Lymphoma Treated with Varying Doses of Pralatrexate Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.
- BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibitionKim R, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.
- Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project NetworkFederico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko Y, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter‐Brown L, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH, Network T. Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network British Journal Of Haematology 2018, 181: 760-769. PMID: 29672827, PMCID: PMC6033106, DOI: 10.1111/bjh.15258.
- The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell ProjectBellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project Haematologica 2018, 103: 1191-1197. PMID: 29599200, PMCID: PMC6029527, DOI: 10.3324/haematol.2017.186577.
- A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell LymphomaFoss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.
- Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphomaHorwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma Blood 2017, 131: 888-898. PMID: 29233821, PMCID: PMC5824337, DOI: 10.1182/blood-2017-08-802470.
- Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell LymphomaCyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
- Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesFlinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies Blood 2017, 131: 877-887. PMID: 29191916, PMCID: PMC6033052, DOI: 10.1182/blood-2017-05-786566.
- Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotinCyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.
- Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.
- Neurolymphomatosis of the thoracic sympathetic chainKaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM. Neurolymphomatosis of the thoracic sympathetic chain Neurology 2017, 89: 1926-1927. PMID: 28939669, PMCID: PMC5664295, DOI: 10.1212/wnl.0000000000004600.
- Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trialFoss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial Journal Of Hematology & Oncology 2017, 10: 154. PMID: 28923081, PMCID: PMC5603163, DOI: 10.1186/s13045-017-0518-8.
- Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationKharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation Transplantation And Cellular Therapy 2017, 23: 1826-1838. PMID: 28797780, DOI: 10.1016/j.bbmt.2017.07.027.
- Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary SyndromeKann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.
- Mycosis Fungoides and Sezary SyndromeFoss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome Hematology/Oncology Clinics Of North America 2017, 31: 297-315. PMID: 28340880, DOI: 10.1016/j.hoc.2016.11.008.
- Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United StatesHsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States Clinical Lymphoma Myeloma & Leukemia 2017, 17: 193-200. PMID: 28209473, DOI: 10.1016/j.clml.2016.10.001.
- Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphomaFoss F, Pro B, Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma Cancer Medicine 2016, 6: 36-44. PMID: 27981793, PMCID: PMC5269566, DOI: 10.1002/cam4.939.
- FISH Panel for Leukemic CTCLWeed J, Gibson J, Lewis J, Carlson K, Foss F, Choi J, Li P, Girardi M. FISH Panel for Leukemic CTCL Journal Of Investigative Dermatology 2016, 137: 751-753. PMID: 27836797, PMCID: PMC5419071, DOI: 10.1016/j.jid.2016.10.037.
- Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administrationPerreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
- Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis FungoidesFoss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Clinical Lymphoma Myeloma & Leukemia 2016, 16: 637-643. PMID: 27637428, DOI: 10.1016/j.clml.2016.08.009.
- Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphomaPro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma Hematological Oncology 2016, 35: 914-917. PMID: 27402335, PMCID: PMC5763404, DOI: 10.1002/hon.2320.
- Autologous Stem Cell Mobilization in the Age of PlerixaforCooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.
- Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trialFoss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial Journal Of Hematology & Oncology 2016, 9: 22. PMID: 26965915, PMCID: PMC4785666, DOI: 10.1186/s13045-016-0243-8.
- Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restrictionGibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction Journal Of The American Academy Of Dermatology 2016, 74: 870-877. PMID: 26874819, PMCID: PMC4835257, DOI: 10.1016/j.jaad.2015.12.018.
- A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trialAdvani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose J. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial British Journal Of Haematology 2015, 172: 535-544. PMID: 26627450, PMCID: PMC5642048, DOI: 10.1111/bjh.13855.
- The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHDNadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
- The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell ProjectBellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project Current Hematologic Malignancy Reports 2015, 10: 448-455. PMID: 26449717, DOI: 10.1007/s11899-015-0291-0.
- Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelScarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model Journal Of Clinical Oncology 2015, 33: 3766-3773. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/jco.2015.61.7142.
- Genomic landscape of cutaneous T cell lymphomaChoi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma Nature Genetics 2015, 47: 1011-1019. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) StudyO'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study Journal Of Clinical Oncology 2015, 33: 2492-2499. PMID: 26101246, PMCID: PMC5087312, DOI: 10.1200/jco.2014.59.2782.
- Romidepsin for the Treatment of Peripheral T‐Cell LymphomaIyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T‐Cell Lymphoma The Oncologist 2015, 20: 1084-1091. PMID: 26099743, PMCID: PMC4571813, DOI: 10.1634/theoncologist.2015-0043.
- Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphomaGibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma Journal Of The American Academy Of Dermatology 2015, 72: 1010-1015.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.
- Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphomaFrankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma Haematologica 2015, 100: 794-800. PMID: 25795722, PMCID: PMC4450625, DOI: 10.3324/haematol.2015.123711.
- Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaHorwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma Annals Of Oncology 2015, 26: 774-779. PMID: 25605745, PMCID: PMC4374388, DOI: 10.1093/annonc/mdv010.
- Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphomaDuvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma Blood 2015, 125: 1883-1889. PMID: 25605368, PMCID: PMC4375715, DOI: 10.1182/blood-2014-09-600924.
- A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphomaFoss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben‐Yehuda D, Beylot‐Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma British Journal Of Haematology 2014, 168: 811-819. PMID: 25404094, DOI: 10.1111/bjh.13222.
- A fatal case of primary cutaneous gamma–delta T‐cell lymphoma complicated by HLH and cardiac amyloidosisGibson JF, Kapur L, Sokhn J, Xu M, Foss FM. A fatal case of primary cutaneous gamma–delta T‐cell lymphoma complicated by HLH and cardiac amyloidosis Clinical Case Reports 2014, 3: 34-38. PMID: 25678971, PMCID: PMC4317209, DOI: 10.1002/ccr3.142.
- Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFoss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma Biomarker Research 2014, 2: 16. PMID: 25279222, PMCID: PMC4181623, DOI: 10.1186/2050-7771-2-16.
- CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literatureJames E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature Leukemia & Lymphoma 2014, 56: 951-957. PMID: 24996443, DOI: 10.3109/10428194.2014.938331.
- Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T‐cell lymphomaGibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T‐cell lymphoma British Journal Of Haematology 2014, 167: 141-144. PMID: 24888971, DOI: 10.1111/bjh.12944.
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesCoiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses Journal Of Hematology & Oncology 2014, 7: 11. PMID: 24456586, PMCID: PMC4016573, DOI: 10.1186/1756-8722-7-11.
- Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoidesLloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides Journal Of The American Academy Of Dermatology 2013, 69: 537-543. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.
- Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphomaChen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Wang C, Dai M, Liu Z, Ma S, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphoma American Journal Of Hematology 2013, 88: 606-611. PMID: 23619945, PMCID: PMC3902049, DOI: 10.1002/ajh.23463.
- Treatment strategies for peripheral T-cell lymphomasFoss FM. Treatment strategies for peripheral T-cell lymphomas Best Practice & Research Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.
- A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT studyFoss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study Leukemia & Lymphoma 2013, 54: 1373-1379. PMID: 23278639, DOI: 10.3109/10428194.2012.742521.
- Pralatrexate: treatment of T-cell non-Hodgkins lymphomaParker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkins lymphoma Future Oncology 2013, 9: 21-29. PMID: 23252560, DOI: 10.2217/fon.12.168.
- Long‐term treatment of CTCL with ECPKnobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long‐term treatment of CTCL with ECP Photodermatology Photoimmunology & Photomedicine 2012, 28: 250-257. PMID: 22971190, DOI: 10.1111/j.1600-0781.2012.00689.x.
- Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non‐Hodgkin lymphomaBi X, Zheng T, Lan Q, Xu Z, Chen Y, Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ, Rothman N, Zhang Y. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non‐Hodgkin lymphoma American Journal Of Hematology 2012, 87: 766-769. PMID: 22649007, PMCID: PMC3576861, DOI: 10.1002/ajh.23244.
- Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin LymphomaKim C, Zheng T, Lan Q, Chen Y, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma Cancer Epidemiology Biomarkers & Prevention 2012, 21: 866-868. PMID: 22374993, PMCID: PMC3394153, DOI: 10.1158/1055-9965.epi-12-0010.
- Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL StudyFoss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study Clinical Lymphoma Myeloma & Leukemia 2012, 12: 238-243. PMID: 22542448, DOI: 10.1016/j.clml.2012.01.010.
- Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaHorwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma Blood 2012, 119: 4115-4122. PMID: 22394596, DOI: 10.1182/blood-2011-11-390211.
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic TherapyCoiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy Journal Of Clinical Oncology 2012, 30: 631-636. PMID: 22271479, DOI: 10.1200/jco.2011.37.4223.
- T-cell lymphomas in South america and europe.Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabús R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M. T-cell lymphomas in South america and europe. Revista Brasileira De Hematologia E Hemoterapia 2012, 34: 42-7. PMID: 23049383, PMCID: PMC3459617, DOI: 10.5581/1516-8484.20120013.
- Polymorphisms in immune function genes and non-Hodgkin lymphoma survivalAschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival Journal Of Cancer Survivorship 2011, 6: 102-114. PMID: 22113576, PMCID: PMC3326600, DOI: 10.1007/s11764-010-0164-4.
- Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair ProteinsQuerfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins Clinical Cancer Research 2011, 17: 5748-5754. PMID: 21747120, PMCID: PMC3725971, DOI: 10.1158/1078-0432.ccr-11-0556.
- Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphomaFoss FM. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma Expert Opinion On Drug Metabolism & Toxicology 2011, 7: 1141-1152. PMID: 21726160, DOI: 10.1517/17425255.2011.595404.
- Predictors of complete responses with denileukin diftitox in cutaneous T‐cell lymphomaFoss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T‐cell lymphoma American Journal Of Hematology 2011, 86: 627-630. PMID: 21674574, DOI: 10.1002/ajh.22039.
- Evolving therapy of peripheral T-cell lymphoma: 2010 and beyondFoss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.
- Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical SolutionCooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.
- Peripheral T-cell lymphomaFoss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.
- Relapsed and refractory PTCL—into the therapeutic abyssFoss F. Relapsed and refractory PTCL—into the therapeutic abyss Nature Reviews Clinical Oncology 2011, 8: 321-322. PMID: 21468128, DOI: 10.1038/nrclinonc.2011.51.
- Molecular Predictors of Response in Aggressive T-cell LymphomasFoss FM. Molecular Predictors of Response in Aggressive T-cell Lymphomas The Cancer Journal 2011, 17: 142-148. PMID: 21427558, DOI: 10.1097/ppo.0b013e31821828b7.
- Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) Journal Of The American Academy Of Dermatology 2010, 64: 352-404. PMID: 21145619, DOI: 10.1016/j.jaad.2010.08.037.
- Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology And Oncology 2010, 8: 1-15. PMID: 21491667.
- Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphomaChen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, Dai M, Li Y, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma Blood 2010, 117: 585-590. PMID: 20952689, PMCID: PMC3031482, DOI: 10.1182/blood-2010-07-295097.
- Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapyBerger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, Edelson R. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy Blood 2010, 116: 4838-4847. PMID: 20720185, PMCID: PMC3321745, DOI: 10.1182/blood-2009-11-256040.
- Enhancing Existing Approaches to Peripheral T-Cell LymphomaFoss FM. Enhancing Existing Approaches to Peripheral T-Cell Lymphoma Seminars In Hematology 2010, 47: s8-s10. PMID: 20359584, DOI: 10.1053/j.seminhematol.2010.01.012.
- Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut womenHan X, Zheng T, Foss F, Holford TR, Shuangge M, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women Leukemia & Lymphoma 2010, 51: 1047-1054. PMID: 20350273, PMCID: PMC3110752, DOI: 10.3109/10428191003690364.
- Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphomaLansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma Cancer Management And Research 2010, Volume 2: 53-59. PMID: 21188096, PMCID: PMC3004568, DOI: 10.2147/cmar.s5009.
- Current and Emerging Treatment Strategies for Cutaneous T-cell LymphomaLansigan F, Foss FM. Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma Drugs 2010, 70: 273-286. PMID: 20166766, DOI: 10.2165/11532190-000000000-00000.
- Alcohol consumption and non-Hodgkin lymphoma survivalHan X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival Journal Of Cancer Survivorship 2009, 4: 101-109. PMID: 20039144, PMCID: PMC3141078, DOI: 10.1007/s11764-009-0111-4.
- The importance of accurately characterizing lymphoproliferative disease.Foss FM. The importance of accurately characterizing lymphoproliferative disease. Oncology 2009, 23: 1168, 1170. PMID: 20043467.
- Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survivalHan X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival American Journal Of Hematology 2009, 85: 51-56. PMID: 20029944, PMCID: PMC2964927, DOI: 10.1002/ajh.21580.
- Advances in the treatment of T-cell lymphomas.Foss F. Advances in the treatment of T-cell lymphomas. Clinical Advances In Hematology And Oncology 2009, 7: 1-14; quiz 15-6. PMID: 20068547.
- Reduced-Intensity and Nonmyeloablative Conditioning RegimensFoss F, van Besien K. Reduced-Intensity and Nonmyeloablative Conditioning Regimens 2008, 144: 209-232. PMID: 19779868, DOI: 10.1007/978-0-387-78580-6_9.
- Cutaneous T-cell LymphomaLansigan F, Choi J, Foss FM. Cutaneous T-cell Lymphoma Hematology/Oncology Clinics Of North America 2008, 22: 979-996. PMID: 18954747, DOI: 10.1016/j.hoc.2008.07.014.
- Mycosis Fungoides: Pathophysiology and Emerging TherapiesDuvic M, Foss FM. Mycosis Fungoides: Pathophysiology and Emerging Therapies Seminars In Oncology 2007, 34: s21-s28. PMID: 18086343, DOI: 10.1053/j.seminoncol.2007.11.006.
- Cutaneous T-cell lymphoma: Biologic targets for therapyChoi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy Current Hematologic Malignancy Reports 2007, 2: 272-277. PMID: 20425380, DOI: 10.1007/s11899-007-0037-8.
- Efficacy of Denileukin Diftitox in Subcutaneous Panniculitis-Like T-Cell LymphomaHathaway T, Subtil A, Kuo P, Foss F. Efficacy of Denileukin Diftitox in Subcutaneous Panniculitis-Like T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2007, 7: 541-545. PMID: 18021473, DOI: 10.3816/clm.2007.n.040.
- Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell LymphomaOlsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma Journal Of Clinical Oncology 2007, 25: 3109-3115. PMID: 17577020, DOI: 10.1200/jco.2006.10.2434.
- Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphomaWhittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma Cancer Treatment Reviews 2007, 33: 146-160. PMID: 17275192, DOI: 10.1016/j.ctrv.2006.08.006.
- Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. The Yale Journal Of Biology And Medicine 2006, 79: 169-72. PMID: 17940627, PMCID: PMC1994805.
- Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin DiftitoxChin KM, Foss FM. Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox Clinical Lymphoma Myeloma & Leukemia 2006, 7: 199-204. PMID: 17229335, DOI: 10.3816/clm.2006.n.059.
- A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesDuvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides Journal Of The American Academy Of Dermatology 2006, 55: 807-813. PMID: 17052486, DOI: 10.1016/j.jaad.2006.06.038.
- The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell TransplantationFoss FM. The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation Seminars In Hematology 2006, 43: s35-s43. PMID: 16549113, DOI: 10.1053/j.seminhematol.2005.12.007.
- IntroductionFoss F, Whittaker S. Introduction Seminars In Oncology 2006, 33: 1-2. PMID: 16516667, DOI: 10.1053/j.seminoncol.2005.12.014.
- Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related SymptomsDummer R, Foss F, Dreno B, Bagot M. Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms Seminars In Oncology 2006, 33: 26-32. PMID: 16516673, DOI: 10.1053/j.seminoncol.2005.12.020.
- Clinical Experience With Denileukin Diftitox (ONTAK)Foss F. Clinical Experience With Denileukin Diftitox (ONTAK) Seminars In Oncology 2006, 33: 11-16. PMID: 16516670, DOI: 10.1053/j.seminoncol.2005.12.017.
- Immunomodulatory Effects of RexinoidsFoss F. Immunomodulatory Effects of Rexinoids Seminars In Oncology 2006, 33: 21-25. PMID: 16516672, DOI: 10.1053/j.seminoncol.2005.12.019.
- Activity of Gallium Nitrate in Refractory Peripheral T-Cell LymphomaHuang Z, Higgins B, Foss F. Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia 2005, 6: 43-45. PMID: 15989706, DOI: 10.3816/clm.2005.n.026.
- Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factorsFoss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors Bone Marrow Transplantation 2005, 35: 1187-1193. PMID: 15852025, DOI: 10.1038/sj.bmt.1704984.
- A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphomaFoss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma Blood 2005, 106: 454-457. PMID: 15811959, DOI: 10.1182/blood-2004-11-4570.
- Nucleoside analogs and antimetabolite therapies for myelodysplastic syndromeFoss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome Best Practice & Research Clinical Haematology 2004, 17: 573-584. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.
- Mycosis fungoides and the Sézary syndromeFoss F. Mycosis fungoides and the Sézary syndrome Current Opinion In Oncology 2004, 16: 421-428. PMID: 15314509, DOI: 10.1097/00001622-200409000-00002.
- Interleukin-2 receptor–directed therapies for cutaneous lymphomasFoss FM, Waldmann TA. Interleukin-2 receptor–directed therapies for cutaneous lymphomas Hematology/Oncology Clinics Of North America 2003, 17: 1449-1458. PMID: 14710895, DOI: 10.1016/s0889-8588(03)00110-2.
- Novel agents for cutaneous T-cell lymphomaKuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma Hematology/Oncology Clinics Of North America 2003, 17: 1459-1466. PMID: 14710896, DOI: 10.1016/s0889-8588(03)00112-6.
- Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/LymphomaDiVenuti G, Nawgiri R, Foss F. Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma Clinical Lymphoma Myeloma & Leukemia 2003, 4: 176-178. PMID: 14715100, DOI: 10.3816/clm.2003.n.027.
- Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host diseaseChan GW, Foss FM, Klein AK, Sprague K, Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease Transplantation And Cellular Therapy 2003, 9: 753-759. PMID: 14677114, DOI: 10.1016/j.bbmt.2003.08.002.
- Peripheral T- cell lymphomas: diagnosis and managementDearden CE, Foss FM. Peripheral T- cell lymphomas: diagnosis and management Hematology/Oncology Clinics Of North America 2003, 17: 1351-1366. PMID: 14710889, DOI: 10.1016/s0889-8588(03)00119-9.
- Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic ApproachesFoss F. Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches Leukemia & Lymphoma 2003, 44: s55-s61. PMID: 15202526, DOI: 10.1080/10428190310001623757.
- Extracorporeal Photopheresis in the Treatment of Graft-vs-Host DiseaseFoss FM. Extracorporeal Photopheresis in the Treatment of Graft-vs-Host Disease Journal Of Cutaneous Medicine And Surgery 2003, 7: 13-17. PMID: 12958702, DOI: 10.1177/12034754030070s404.
- Persistence of host dendritic cells after transplantation is associated with graft-versus-host diseaseChan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease Transplantation And Cellular Therapy 2003, 9: 170-176. PMID: 12652467, DOI: 10.1016/s1083-8791(03)70006-8.
- Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ geneShao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene Leukemia Research 2002, 26: 1077-1083. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.
- ALTERED BIOLOGICAL ACTIVITY ASSOCIATED WITH C-TERMINAL MODIFICATIONS OF IL-7Görgün G, van der Spek J, Cosenza L, Menevse A, Foss F. ALTERED BIOLOGICAL ACTIVITY ASSOCIATED WITH C-TERMINAL MODIFICATIONS OF IL-7 Cytokine 2002, 20: 17-22. PMID: 12441142, DOI: 10.1006/cyto.2002.1974.
- Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitoxGorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox Blood 2002, 100: 1399-1403. PMID: 12149223, DOI: 10.1182/blood-2002-01-0300.
- Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host diseaseGorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease Blood 2002, 100: 941-947. PMID: 12130506, DOI: 10.1182/blood-2002-01-0068.
- A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S. A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96 Gynecologic Oncology 2002, 85: 464-468. PMID: 12051875, DOI: 10.1006/gyno.2002.6647.
- Immunologic mechanisms of antitumor activityFoss FM. Immunologic mechanisms of antitumor activity Seminars In Oncology 2002, 29: 5-11. PMID: 12068382, DOI: 10.1053/sonc.2002.33076.
- Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell linesCosenza L, Gorgun G, Urbano A, Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines Cellular Signalling 2002, 14: 317-325. PMID: 11858939, DOI: 10.1016/s0898-6568(01)00245-5.
- Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®)Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®) Clinical Lymphoma Myeloma & Leukemia 2002, 2: 222-228. PMID: 11970761, DOI: 10.3816/clm.2002.n.003.
- STRUCTURE FUNCTION ANALYSIS OF INTERLEUKIN 7: REQUIREMENT FOR AN AROMATIC RING AT POSITION 143 OF HELIX DvanderSpek JC, Sutherland JA, Gill BM, Gorgun G, Foss FM, Murphy JR. STRUCTURE FUNCTION ANALYSIS OF INTERLEUKIN 7: REQUIREMENT FOR AN AROMATIC RING AT POSITION 143 OF HELIX D Cytokine 2002, 17: 227-233. PMID: 12027403, DOI: 10.1006/cyto.2002.1004.
- Diphtheria fusion protein therapy of chemoresistant malignancies.Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Current Cancer Drug Targets 2002, 2: 19-36. PMID: 12188918, DOI: 10.2174/1568009023333944.
- Transformation in mycosis fungoides: The role of methotrexateAbd-el-Baki J, Demierre MF, Li N, Foss FM. Transformation in mycosis fungoides: The role of methotrexate Journal Of Cutaneous Medicine And Surgery 2002, 6: 109-116. PMID: 11992182, DOI: 10.1007/s10227-001-0040-y.
- Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cellsUrbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells Biochemical Pharmacology 2002, 63: 689-692. PMID: 11992636, DOI: 10.1016/s0006-2952(01)00916-9.
- Lymphoma of the SkinConnors JM, Hsi ED, Foss FM. Lymphoma of the Skin Hematology 2002, 2002: 263-282. PMID: 12446427, DOI: 10.1182/asheducation-2002.1.263.